Ariceum's SSTR2-Targeting SCLC Therapy Gets FDA Orphan Status

Tejal Somvanshi

A promising new lung cancer treatment has earned special recognition from the FDA.

Photo source: Doc James (CC BY-SA 3.0)

Ariceum Therapeutics developed this treatment to target SSTR2 receptors on cancer cells.

Photo source: SIB (CC BY 4.0)

The FDA granted it "Orphan Drug" status, supporting treatments for rare diseases– which speeds up development and offers exclusive market protection for seven years.

Photo source: Picryl (PDM 1.0)

The treatment aims to help patients with Small Cell Lung Cancer (SCLC), a hard-to-treat cancer.

Photo source: Nephron (CC BY-SA 3.0)

SCLC often spreads before diagnosis in two-thirds of cases, with only 5-10% surviving five years.

Photo source: Magnus Manske (CC BY-SA 2.0)

The therapy uses a theranostic approach — combining diagnosis and treatment in one method.

Photo source: RDNE Stock Project (PDM 1.0)

The diagnostic tool identifies patients likely to benefit, enabling personalized care.

Photo source: RDNE Stock Project(PDM 1.0)

Clinical trials, named SANTANA-225, are set to begin in early 2025.

Photo source: Nick Youbgson (CC BY-SA 3.0)

FDA recognition highlights the treatment's potential for patients with limited options.

Photo source: Navy Medicine (CC0 1.0)

This development brings new hope to families affected by aggressive lung cancer.

Photo source: Markllos (CC BY-SA 3.0)